Recently, revolutionary therapeutic strategies have been used to restore T cell-mediated anti-tumor immunity in HNSCC by targeting immune checkpoint molecules, such a PD-L1 and PD-1. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.